TNFSF10 and Alzheimer disease: Giuseppina et al reported that when they treated their AD model with monoclonal antibody of TRAIL, they observed microscopic pathological improvement which includes reduced expression of TRAIL itself, its receptors and amyloid‐β, mitigation of inflammation and reduction in neurofibrillary tangles and macroscopic improvement of cognitive function.98